Why FDA Approval Does Not Mean EU Market Access
I reviewed a PMA submission package that took four years and $15 million to complete. The sponsor assumed the same clinical data would support their MDR Technical Documentation. It did not. The Notified Body requested three additional clinical studies and a complete redesign of the clinical evaluation report.
This is not an isolated case. It happens more often than sponsors expect.
When manufacturers cross the Atlantic with a Class III device, they often discover that regulatory symmetry is an illusion. Both FDA and EU regulators demand rigorous clinical evidence. Both require premarket approval pathways. Both scrutinize safety and performance claims.
But the structure of the clinical evidence, the logic of the evaluation, and the tolerance for gaps are fundamentally different.
Understanding these differences is not about comparing forms and checklists. It is about understanding how each system reasons about risk, evidence, and clinical benefit.
The Clinical Data Paradigm Under PMA
The FDA Premarket Approval process under 21 CFR 814 is a product-specific authorization. The clinical investigation is designed to demonstrate that the device is safe and effective for its intended use in the U.S. population.
The emphasis is on a pivotal clinical trial. This trial is prospective, controlled, and statistically powered to answer a specific clinical question. The study protocol is agreed upon with the FDA before enrollment begins. The data is analyzed according to predefined endpoints. The results are submitted as part of the PMA application.
The FDA does not require a formal literature review in the European sense. Supporting literature may be included, but it serves as context. The pivotal trial is the cornerstone. If the trial meets its endpoints and the device meets its specifications, the PMA is typically granted.
The logic is: prove your device works in a controlled setting with this population under these conditions.
FDA PMA relies on a product-specific clinical trial to answer a narrow clinical question. The evidence is generated for that device in that indication. Generalization to other devices or populations is not expected.
The Clinical Evidence Logic Under MDR Article 61
The MDR does not ask for a single pivotal trial. It asks for a clinical evaluation.
A clinical evaluation under Article 61 and MDCG 2020-5 is a systematic and planned appraisal of all available clinical data. This includes clinical investigations conducted by the manufacturer, but it also includes published literature, post-market data, and where applicable, data from equivalent devices.
The question the clinical evaluation answers is different. It is not: does this device meet its endpoints in a controlled trial? It is: does the current body of clinical evidence support the safety and performance claims for this device in its intended clinical context?
The evaluation must address all significant residual risks identified in the risk management file. It must demonstrate that the benefit-risk ratio is favorable. It must show that the device performs as intended across its full range of intended users, patients, and clinical conditions.
This is why a literature review is not optional. It is central. The manufacturer must search for all relevant clinical data, appraise it systematically, and integrate it into a coherent argument.
Manufacturers submit a PMA clinical study report as their clinical evaluation. The Notified Body responds:
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report). MDR Article 61, FDA 21 CFR 814
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
